Ask AI
ProCE Banner Activity

ARCHES: Post Hoc Analysis of 5-Yr OS Outcomes for Phase III Trial of Enzalutamide + ADT vs Placebo + ADT in Patients With mHSPC

Conference Coverage
Slideset

A post hoc analysis with a 5-year median follow-up from the phase III ARCHES trial showed a significant, sustained survival benefit with enzalutamide plus androgen-deprivation therapy (ADT) vs placebo plus ADT in patients with mHSPC.

Released: June 01, 2025

Expiration: November 30, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Astellas.

Astellas